Biopharmaceutical company Geneuro (Euronext Paris:GNRO) announced on Tuesday the completion of patient recruitment for its Phase 2 trial evaluating temelimab (GNbAC1) against long-COVID.
The trial, titled 'Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome', involves a randomised, placebo-controlled, biomarker-based approach and has enrolled 203 patients across 14 clinical centres in Switzerland, Spain and Italy.
Focused on assessing the impact of temelimab on the clinical course of symptoms, including fatigue and cognitive impairment, all enrolled patients will receive six intravenous infusions of temelimab or placebo over 24 weeks. Notably, recruitment for the trial has revealed that over one third of patients with long-COVID syndromes screened positive for the presence of the pathogenic W-ENV protein in their blood. W-ENV is suspected to play a significant role in persistent inflammation and neurological symptoms in these patients.
The trial's objective is to determine the extent to which temelimab, a highly specific neutralising anti-W-ENV-antibody, can alleviate clinical symptoms in long-COVID patients. Success in this clinical endeavour could position temelimab as the first disease-modifying therapy for this underserved indication. Top-line results are expected by June 2024, potentially opening accelerated pathways for drug availability to the affected population.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration